Pyxis Oncology, Inc.
Pyxis Oncology, Inc. (PYXS): 6 pipeline candidates · ~5 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
4.8 months
D/E 1.06 · 1% dilution
Lead: Phase 1/Phase 2
6 candidates
N/A
N/A
A transparent, data-derived signal for Pyxis Oncology, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$120.4M
Cash
$7.2M
Quarterly Burn
$26.0M
Runway
4.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| APX005M | Phase 1 |
| APX005M treatment for newly diagnosed DIPG patients | Phase 1 |
| micvotabart pelidotin | Phase 1/Phase 2 |
| PYX-106 | Phase 1 |
| PYX-107 | Phase 2 |
| PYX-201 | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
74
Total value held
$27.6M
| Holder | Shares | Value |
|---|---|---|
| laurion capital management lp | 4,997,333 | $7.3M |
| vanguard capital management llc | 4,067,020 | $5.9M |
| atle fund management ab | 197,036 | $1.6M |
| palo alto investors lp | 1,010,510 | $1.5M |
| 683 capital management, llc | 896,263 | $1.3M |
| renaissance technologies llc | 888,680 | $1.3M |
| blackrock, inc. | 788,839 | $1.2M |
| geode capital management, llc | 598,121 | $874K |
| jacobs levy equity management, inc | 460,997 | $673K |
| millennium management llc | 397,625 | $581K |
Showing top 10 of 74 institutional holders of Pyxis Oncology, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Pyxis Oncology, Inc.'s pipeline?
Pyxis Oncology, Inc. (PYXS) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Pyxis Oncology, Inc.'s lead drug candidate?
Pyxis Oncology, Inc.'s most advanced tracked candidate is APX005M (Phase 1) for Melanoma.
What is Pyxis Oncology, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Pyxis Oncology, Inc. has approximately 4.8 months of cash runway.
What is Pyxis Oncology, Inc.'s market capitalization?
Pyxis Oncology, Inc.'s market capitalization is approximately $120.4M.
Who is the CEO of Pyxis Oncology, Inc.?
Mr. Thomas Civik is the chief executive officer of Pyxis Oncology, Inc. (PYXS).
Get the full picture on Pyxis Oncology, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.